Schedule of Financial Information by Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Segment Reporting Information [Line Items]
Net revenues	$ 5,736	$ 12,111	$ 17,162	$ 26,792
Cost of revenues (excluding amortization of acquired intangible assets)	5,242	2,123	8,796	3,763
Direct expenses	15,986	19,707	33,976	39,578
Segment contribution	(15,492)	(9,719)	(25,610)	(16,549)
Indirect expenses	372	456	740	1,002
Loss from operations	(15,864)	(10,175)	(26,350)	(17,551)
Cell Therapy [Member]
Segment Reporting Information [Line Items]
Net revenues	759		1,023
Cost of revenues (excluding amortization of acquired intangible assets)
Direct expenses	2,927	3,422	6,184	8,887
Segment contribution	(2,168)	(3,422)	(5,161)	(8,887)
BioBanking [Member]
Segment Reporting Information [Line Items]
Net revenues	1,275	1,278	2,683	2,565
Cost of revenues (excluding amortization of acquired intangible assets)	220	537	429	714
Direct expenses	387	447	756	863
Segment contribution	668	294	1,498	988
Degenerative Disease [Member]
Segment Reporting Information [Line Items]
Net revenues	3,702	10,833	13,456	24,227
Cost of revenues (excluding amortization of acquired intangible assets)	5,022	1,586	8,367	3,049
Direct expenses	1,854	5,784	6,601	10,198
Segment contribution	(3,174)	3,463	(1,512)	10,980
Other [Member]
Segment Reporting Information [Line Items]
Net revenues
Cost of revenues (excluding amortization of acquired intangible assets)
Direct expenses	10,818	10,054	20,435	19,630
Segment contribution	(10,818)	(10,054)	(20,435)	(19,630)
Indirect expenses	372	456	740	1,002
Amortization	372	456	740	1,002
Total other	$ 372	$ 456	$ 740	$ 1,002